CSNK2B and non-small cell lung carcinoma: Utilization of CK2 inhibitors or knockdown of CK2B expression can upregulate TBX21 expression through HDAC8‐mediated epigenetic reprogramming, restoring the effector function of CD8+ T cells and enhancing the efficacy of anti‐PD‐1 therapy in NSCLC.